B8299

N-Butyldeoxynojirimycin

film (dried in situ), ≥98% (TLC)

• Sinónimos: Miglustat, NB-DNJ
• Fórmula empírica (notación de Hill): C₁₀H₂₁NO₄
• Número de CAS: 72599-27-0
• Peso molecular: 219.28
• MDL number: MFCD00272581
• UNSPSC Code: 12352200
• PubChem Substance ID: 24892070
• NACRES: NA.32

Propiedades

• product name: N-Butyldeoxynojirimycin, film (dried in situ)
• assay: ≥98% (TLC)
• Quality Level: 200
• form: film (dried in situ)
• solubility: water: 9.80-10.20 mg/mL, clear, colorless
• storage temp.: 2-8°C
• SMILES string: CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
• InChI: 1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
• InChI key: UQRORFVVSGFNRO-UTINFBMNSA-N
• Gene Information: human ... UGCG(7357)

Descripción

General description

N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.

Application

N-Butyldeoxynojirimycin has been used:

• in the inhibition of glycolipid synthesis in neuroblastoma cells
• in the inhibition the ceramide-specific glycosyltransferase in hepatocytes
• in the inhibition of β-glucosidase (GBA2) using fluorescence- activity assay in human embryonic kidney (HEK293) cells.

Biochem/physiol Actions

N-Butyldeoxynojirimycin is an inhibitor of glucosyltransferase and α-glucosidases. N-Butyldeoxynojirimycin, also known as misglustat, reduces glycolipid levels by substrate reduction therapy (SRT) and is effectively used for the treatment of glycosphingolipid lysosomal storage disorder, Gaucher disease.

α-glucosidase Inhibitor

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)